Interim Results

Smith & Nephew Plc 01 August 2002 1 August 2002 CONTINUED STRONG GROWTH FOR SMITH & NEPHEW Smith & Nephew, the global advanced medical devices company, announces its interim results for the half year ended 29 June 2002. Key points: • Underlying sales up 14% • Acquisitions added another 4% to sales • Profit before tax and exceptional items up 13% • EPS before exceptional items up 11%, underlying EPS up 18% • Further progress expected in second half Dudley Eustace, Chairman, said : 'All businesses are performing well and demand for our products continues to be strong worldwide. Our sales performance was robust in all our businesses and our Orthopaedics division was again the fastest growing manufacturer of hip and knee implants. We are therefore well placed to make further progress in the second half and beyond.' Enquiries: Chris O'Donnell, Chief Executive Tel: +44 (0)20 7401 7646 Smith & Nephew plc Peter Hooley, Finance Director Tel: +44 (0)20 7401 7646 Smith & Nephew plc Margaret Stewart, Group Director Corporate Affairs Tel: +44 (0)20 7401 7646 Smith & Nephew plc Jonathan Birt Tel: +44 (0)20 7831 3113 Financial Dynamics A presentation for analysts will be held at the City Presentation Centre, 4 Chiswell Street, Finsbury Square, London EC1Y 4UP at 9.30am today. A tele-conference call for analysts will be held at 3pm today: please call Mo Noonan at Financial Dynamics on +44 (0)20 7831 3113 for details. The morning meeting will be webcast as will the tele-conference at 3pm on www.smith-nephew.com/interimreport. High resolution photographs are available to the media free of charge at www.newscast.co.uk Trading Results and Overview Our markets throughout the world continued to be strong in the first half of 2002 and Smith & Nephew sustained its pace of growth. Demand for our products in orthopaedics, endoscopy and advanced wound management continues to be strong. For the third year running our orthopaedics business was the fastest growing implant company. Sales in our ongoing businesses again performed strongly, rising 17%. Within this, underlying growth was 14%, aided by our programme of new product launches and investment in sales forces. Sales price increases accounted for 11/2% of underlying growth. Adverse currency translation reduced overall sales growth by 1%. We are also selectively making acquisitions to augment our business base, and these accounted for 4% of reported sales growth in the first half. As part of this acquisition programme, we purchased ORATEC Interventions, Inc., in March, in order to gain a strong base in radio frequency technology for minimally invasive surgery. In March, we completed our restructuring programme with the disposal of Rehabilitation to AbilityOne for £71m paid in cash, plus a 211/2% retained interest in the enlarged company so as to benefit from the substantial value we believe will be created by combining the two businesses. Ongoing margins of 161/2% are after absorbing 1% of dis-synergies from last year's divestments and Rehabilitation this year and from incorporating goodwill amortisation on the ORATEC acquisition. Profit before tax and exceptional items amounted to £94m, an increase of 13%. This comprises £87m of operating profit from ongoing operations, £2m of profit from discontinued operations (principally Rehabilitation), an £11m share of the profits of BSN Medical and AbilityOne, less £6m of interest cost. Amortisation of acquisition goodwill charged to operating profit was £8m, of which £2m related to ORATEC. Earnings per share, exceptional items and cash flow The effective ordinary tax charge was 32%, resulting in earnings per share before exceptional items of 6.89p, an 11% increase. Adjusting for the dilutive effects of the disposals this and last year, the formation of the BSN Medical joint venture and from incorporating goodwill amortisation on the acquisition of ORATEC, the underlying increase in earnings per share before exceptional items was 18%. Exceptional items comprise profit on disposals of £19m, principally Rehabilitation, less £9m of rationalisation and acquisition integration costs and an £8m write down in the value of our equity investment in Advanced Tissue Sciences, Inc. Operating cash flow was £38m after £9m of outgoings on rationalisation and acquisition integration. The net cost of acquisitions, principally ORATEC, was £194m and the proceeds from disposing of Rehabilitation were £71m. Net debt closed at £350m after benefiting from £28m of currency translation. Dividend An interim dividend of 1.80 pence per share (2001 : 1.75 pence) will be paid on 15 November 2002 to shareholders on the register at the close of business on 18 October 2002. Shareholders may participate in the company's dividend reinvestment plan. Operating Review Orthopaedics Demand for hip and knee replacements and for trauma products shows no sign of diminishing. Our orthopaedics business achieved increased underlying growth of 20%, maintaining its position as the fastest growing manufacturer of orthopaedic implants. Hip and knee implants grew at 27% and trauma sales grew 8%. New products Oxinium and Supartz contributed 10% to implant sales growth, and took knees to a notable 37% growth. Hip sales grew at 16%. Additional Oxinium knee components were launched in both the Genesis and Profix ranges. We continued to invest in computer aided surgery, where we achieved a 510k approval from the FDA for knee procedures and extended our agreement for the development of software and instrumentation with Medtronic. The forthcoming retirement of Larry Papasan as President of the Orthopaedics division and the appointment on 1 May of David Illingworth as his successor were announced. Endoscopy The requirement for minimally invasive surgery for injuries, mainly caused by sport, remains strong. Endoscopy achieved an underlying sales growth of 10% in the first half, with the acquisition of ORATEC at the end of March contributing an additional 6% to this. Arthroscopic repair performed strongly and Trivex, our technique for varicose vein removal, also made a useful impact. Integration of ORATEC is proceeding to plan, with cost savings on target. We have already launched a bipolar radio-frequency resection system to complement ORATEC's monopolar tissue shrinkage products. We continue to improve the percentage of new products to sales in Endoscopy and to date this year have achieved 15%. The addition of the new radio-frequency products from ORATEC and our FasT-Fix and TwinFix suturing devices will accelerate this still further. Both the new headquarters in Andover, Massachusetts, and our extended Mansfield, Massachusetts, manufacturing facility are now fully operational. Advanced wound management The growing population of elderly people underpins the strong demand for our advanced wound healing products, a market we continue to lead. Sales in advanced wound management grew at an underlying 11%, with a further 8% arising at the half year from the acquisitions of Beiersdorf's advanced wound management business and Acticoat last year. Our lead product Allevyn again demonstrated strong sales growth of 23% and we continue to develop this range to meet new needs. Our burns products continue to do well and the global rollout of Acticoat, the silver-based dressing, is being met with enthusiasm by wound management specialists and nurses. Dermagraft, our bio-engineered dermis for patients with hard to heal diabetic foot ulcers, received initial reimbursement approval in the US in April. Sales and extension of reimbursement coverage across the US are meeting their respective targets. BSN Medical joint venture At BSN, trading and integration rationalisation remains on target, with a consequential improvement in profitability to a 12% margin. Outlook We are pleased with the progress of the Group and particularly with the strong growth and increased market share in orthopaedics. Our investment in new products and strengthened sales force is paying off. Our underlying margins continue to improve and we expect this to continue in the second half of the year. The medical devices sector continues to demonstrate strong growth characteristics and we expect to make further progress in the second half of the year and beyond. Unaudited Group Profit and Loss Account for the Half Year Ended 29 June 2002 Year 2001 2001 2002 Restated# £m Notes £m £m Turnover 1,2 943.0 Ongoing operations 531.9 454.1 35.3 Operations contributed to the joint venture - 35.3 _____ _____ _____ 978.3 Continuing operations 531.9 489.4 103.4 Discontinued operations 3 26.2 58.4 _____ _____ _____ 1,081.7 Group turnover 558.1 547.8 123.6 Share of joint venture 79.3 41.9 _____ _____ _____ 1,205.3 637.4 589.7 _____ _____ _____ Operating profit Ongoing operations 160.4 - before exceptional items 87.1 77.7 (19.3) - exceptional items* 5 (15.3) (14.0) _____ _____ _____ 141.1 71.8 63.7 Operations contributed to the joint venture 3.6 - before exceptional items 2 - 3.6 (1.8) - exceptional items* 5 - - _____ _____ _____ 142.9 Continuing operations 71.8 67.3 11.1 Discontinued operations 3 2.1 6.9 _____ _____ _____ 154.0 73.9 74.2 Share of operating profit of the joint venture 12.8 - before exceptional items 2 9.4 4.0 (5.0) - exceptional items* 6 (1.3) (2.5) _____ _____ _____ 161.8 82.0 75.7 - Share of operating profit of the associated undertaking 3 1.4 - _____ ____ _____ 161.8 83.4 75.7 49.2 Discontinued operations - net profit on disposals* 3 19.0 47.1 _____ _____ _____ 211.0 Profit on ordinary activities before interest 102.4 122.8 (17.4) Interest 7 (6.3) (9.5) _____ _____ _____ 193.6 Profit on ordinary activities before taxation 96.1 113.3 64.0 Taxation 8 45.5 41.2 _____ _____ _____ 129.6 Attributable profit 50.6 72.1 42.9 Ordinary dividends 9 16.7 16.1 _____ _____ _____ 86.7 Retained profit 33.9 56.0 _____ _____ _____ 14.07p Basic earnings per ordinary share 10 5.46p 7.84p 13.95p Diluted earnings per ordinary share 10 5.42p 7.76p Results before exceptional items (*) £170.5m Profit before taxation 11 £93.7m £82.7m 12.83p Adjusted basic earnings per ordinary share 10 6.89p 6.20p 12.72p Adjusted diluted earnings per ordinary share 10 6.84p 6.14p # See note 13 Abridged Group Balance Sheet as at 29 June 2002 Year 2001 2001 2002 Restated# £m Notes £m £m Fixed assets 187.8 Intangible assets 332.8 186.5 245.0 Tangible assets 248.9 233.5 114.0 Investment in joint ventureA 2 112.4 135.3 - Investment in associated undertakingB 3 7.5 - 25.7 Investments 17.7 26.1 _____ _____ _____ 572.5 719.3 581.4 _____ _____ _____ Working capital 232.2 Stocks 241.6 224.5 263.2 Debtors 280.4 277.3 Creditors (21.7) - acquisition consideration (18.2) (23.1) (302.8) - other (303.1) (290.5) _____ _____ _____ 170.9 200.7 188.2 Provisions (55.4) - deferred taxation (54.8) (55.6) _____ _____ (39.9) - other (37.2) (47.3) _____ _____ _____ 648.1 828.0 666.7 _____ _____ _____ 404.6 Share capital and reserves 477.9 369.1 243.5 Net borrowings 350.1 297.6 _____ _____ _____ 648.1 828.0 666.7 _____ _____ _____ A Investment in joint venture comprises goodwill £71.3 million and share of gross assets of £107.8 million less share of gross liabilities £66.7 million. B Investment in associated undertaking comprises goodwill £15.9 million and share of gross assets of £12.5 million less share of gross liabilities £20.9 million. Abridged Movement in Shareholders' Funds for the Half Year Ended 29 June 2002 Year 2001 2001 2002 Restated# £m £m £m 268.0 Opening shareholders' funds as previously reported 404.6 329.6 - Adjustments on adoption of FRS 19 - (61.6) _____ _____ _____ 268.0 Opening shareholders funds - restated 404.6 268.0 129.6 Attributable profit 50.6 72.1 (42.9) Dividends (16.7) (16.1) (8.8) Exchange adjustments 6.0 (8.5) 17.9 Goodwill on disposals/operations contributed to the joint 30.0 17.9 venture 31.8 Unrealised gain on formation of the joint venture - 31.8 (2.1) Movements relating to the QUEST (0.4) - 11.1 Issue of shares 3.8 3.9 _____ _____ _____ 404.6 Closing shareholders' funds 477.9 369.1 _____ _____ _____ # See note 13 Abridged Group Cash Flow for the Half Year Ended 29 June 2002 Year 2001 2001 2002 Restated# £m £m £m 154.0 Operating profit 73.9 74.2 60.3 Depreciation and amortisationC 43.9 30.4 (22.4) Working capital and provisions (38.9) (42.1) _____ _____ _____ 191.9 Net cash inflow from operating activitiesD 78.9 62.5 (72.6) Capital expenditure and financial investment (41.2) (31.0) _____ _____ _____ 119.3 Operating cash flow 37.7 31.5 - Joint venture dividend 2.2 - (16.5) Interest (5.2) (9.3) (76.2) Tax (29.7) (33.4) (42.0) Dividends (26.8) (25.8) (69.3) Acquisitions (193.5) (59.0) 61.7 Disposals 71.8 61.7 12.6 Joint venture formation 5.7 (4.2) 9.0 Issues of ordinary share capital 3.4 3.9 _____ _____ _____ (1.4) Net cash outflow (134.4) (34.6) (5.8) Exchange adjustments 27.8 (26.7) (236.3) Opening net borrowings (243.5) (236.3) _____ _____ _____ (243.5) Closing net borrowings (350.1) (297.6) _____ _____ _____ C Includes goodwill amortisation of £8.1 million (£10.4 million for full year 2001 and £4.5 million at the half year) and £8.0 million exceptional write down against the group's equity investment in Advanced Tissue Sciences, Inc. D After £9.1 million (£23.5 million for full year 2001 and £12.2 million at the half year) of outgoings on rationalisation, acquisition integration and divestment costs. Statement of Total Recognised Gains and Losses for the Half Year Ended 29 June 2002 Year 2001 2001 2002 Restated# £m £m £m 129.6 Attributable profit 50.6 72.1 31.8 Unrealised gain on formation of the joint venture - 31.8 (8.8) Currency translation differences on foreign currency net investments 6.0 (8.5) _____ _____ _____ 152.6 Total recognised gains and losses 56.6 95.4 _____ _____ _____ # See note 13 NOTES TO THE 2002 INTERIM RESULTS 1. Segmental performance for the half year ended 29 June 2002 was as follows: Group Turnover by product Year 2001 2002 2001 Underlying £m £m £m sales growth 404.6 Orthopaedics 235.8 199.4 20% 252.8 Endoscopy 141.7 123.2 10% 285.6 Advanced Wound Management 154.4 131.5 11% _____ _____ _____ _____ 943.0 Ongoing operations 531.9 454.1 14% _____ 35.3 Operations contributed to the joint venture - 35.3 103.4 Discontinued operations 26.2 58.4 _____ _____ _____ 1,081.7 558.1 547.8 _____ _____ _____ Group turnover by geographic market Year 2001 2002 2001 Underlying £m £m £m sales growth 268.4 Europe* 155.6 130.6 13% 534.9 America 303.1 257.6 14% 139.7 Africa, Asia and Australasia 73.2 65.9 15% _____ _____ _____ _____ 943.0 Ongoing operations 531.9 454.1 14% _____ 35.3 Operations contributed to the joint venture - 35.3 103.4 Discontinued operations 26.2 58.4 _____ _____ _____ 1,081.7 558.1 547.8 _____ _____ _____ * Includes United Kingdom sales of £40.8 million (£77.5 million for full year 2001 and £37.0 million at the half year). Underlying sales growth is sales growth adjusted to eliminate the effect of translational currency, acquisitions and disposals. 2. On 1 April 2001, the casting and bandaging and traditional woundcare businesses were contributed to a joint venture with Beiersdorf AG called BSN Medical in return for a 50% equity interest. The results of these businesses prior to contribution represent operations contributed to the joint venture in the group profit and loss account. 3. On 27 March 2002, the rehabilitation business was disposed of to AbilityOne for £71.3 million cash and a 21.5% equity interest in the combined business. AbilityOne is accounted for as an associated undertaking under the net equity method. The results of rehabilitation prior to disposal represent discontinued operations. The net profit on disposal of £17.2 million is stated after deducting £30.0 million of goodwill previously written off to reserves on acquisition. The remaining gain of £1.8 million relates to adjustments in respect of previous disposals. Discontinued operations in 2001 also include the results and net profit on disposal of the ear, nose and throat business. 4. On 28 March 2002, ORATEC Interventions, Inc., a company that applies radio frequency energy to treat joint and spine disorders, was acquired for a net consideration of £190.6 million. The fair value of assets acquired was £26.9 million and goodwill arising was £163.7 million. 5. Operating exceptional items within ongoing operations comprise an £8.0 million write down against the group's equity investment in Advanced Tissue Sciences, Inc., £3.1 million costs of rationalisation consequent on the contribution of businesses to BSN Medical and manufacturing rationalisation (2001 half year £8.7 million; full year £10.4 million) and £4.2 million of acquisition integration costs (2001 half year £5.3 million; full year £8.9 million). Operating exceptional items within operations contributed to the joint venture in 2001 represented manufacturing rationalisation costs. 6. The group's share of exceptional items of the joint venture relates to manufacturing rationalisation costs of BSN Medical. 7. Interest includes £0.8 million (2001 - £0.2 million) in respect of the group's share of the net interest charge of BSN Medical and £0.3 million (2001 - nil) in respect of the group's share of the net interest charge of AbilityOne. 8. The tax charge is based on an estimated effective rate of 32% on the full year's results before exceptional items and includes £15.6 million in respect of the net exceptional items. Of the total, £37.7 million relates to overseas taxation, £2.6 million relates to the group's share of the tax of BSN Medical and £0.3 million relates to the group's share of the tax of AbilityOne. 9. An interim dividend of 1.80 pence per ordinary share (2001 - 1.75 pence per ordinary share) will be paid on 15 November 2002 to all shareholders on the register at the close of business on 18 October 2002. Shareholders may participate in the dividend reinvestment plan. 10. The basic average number of ordinary shares in issue was 926 million (2001 - 920 million). The diluted average number of ordinary shares in issue was 933 million (2001 - 929 million). 11. Results before exceptional items state profit before taxation before charging the cost of exceptional items and the net profit on the disposal of discontinued operations. Adjusted earnings per ordinary share is based on the attributable profit before accounting for these items and associated taxation thereon. 12. The interim financial information has been prepared on the basis of the accounting policies set out in the full annual accounts of the group for the year ended 31 December 2001. The financial information contained in this interim statement does not constitute statutory accounts as defined in Section 240 of the Companies Act 1985. 13. Half year 2001 comparative figures have been restated for the adoption in the 2001 full year results of Financial Reporting Standard 19 and Urgent Issues Task Force Abstract 31. 14. The financial information for the year ended 31 December 2001 has been extracted from the full annual accounts of the group which have been filed with the Registrar of Companies. The auditors' report on those accounts was unqualified. Independent Review Report to Smith & Nephew plc We have been instructed by the company to review the financial information for the six months ended 29 June 2002 which comprises the Group Profit and Loss Account, Abridged Group Balance Sheet, Abridged Group Cash Flow Statement, Statement of Total Recognised Gains and Losses, Abridged Movement in Shareholders' Funds and the related notes 1 to 14. We have read the other information contained in the interim report and considered whether it contains any apparent misstatements or material inconsistencies with the financial information. The interim report, including the financial information contained therein, is the responsibility of, and has been approved by the directors. The directors are responsible for preparing the interim report in accordance with the Listing Rules of the Financial Services Authority which require that the accounting policies and presentation applied to the interim figures should be consistent with those applied in preparing the preceding annual accounts except where any changes, and the reasons for them, are disclosed. We conducted our review in accordance with guidance contained in Bulletin 1999/4 'Review of interim financial information' issued by the Auditing Practices Board for use in the United Kingdom. A review consists principally of making enquiries of group management and applying analytical procedures to the financial information and underlying financial data, and based thereon, assessing whether the accounting policies and presentation have been consistently applied, unless otherwise disclosed. A review excludes audit procedures such as tests of controls and verification of assets, liabilities and transactions. It is substantially less in scope than an audit performed in accordance with United Kingdom Auditing Standards and therefore provides a lower level of assurance than an audit. Accordingly we do not express an audit opinion on the financial information. On the basis of our review we are not aware of any material modifications that should be made to the financial information as presented for the six months ended 29 June 2002. Ernst & Young LLP London 1 August 2002 This information is provided by RNS The company news service from the London Stock Exchange

Companies

Smith & Nephew (SN.)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today